Silence At-A-Glance
| Silence Therapeutics plc (LSE: SLN) is a global leader in the discovery, development and delivery of novel RNA interference (RNAi) therapeutics for the treatment of serious diseases. The company possesses one of the world’s most comprehensive RNAi therapeutic platforms comprised of proprietary delivery technologies, potent siRNA sequences and innovative siRNA structural features – the three areas the company believes to be critical to building, protecting and commercializing RNAi therapeutics. This platform is protected by Silence’s strong intellectual property portfolio which includes more than 200 issued and pending patent applications worldwide. |
Financial Snapshot(SLN: LSE)
For an updated stock quote, please access the link above to the London Stock Exchange.
|
|
Thomas Christély, CEO on Proactive Investors »
Latest News
|
